1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Mitsubishi Tanabe Cuts Ties with Four-year Generics Subsidiary, But Sales Goals Remain

 
• By Daniel Poppy

Mitsubishi Tanabe sold all shares of its Choseido Pharmaceutical subsidiary after not meeting expectations, and must now reassess its generics strategy.

TOKYO - Mitsubishi Tanabe Pharma Corp. was one of the few of Japan’s major pharma companies to be vocal in its pursuit of generic drug growth in Japan and abroad, and has been enthusiastic about the prospects in Japan’s evolving market. The company announced a setback to that plan Oct. 19 by terminating an alliance and severing business ties with its generics subsidiary Choseido Pharmaceutical Co. Ltd.

Mitsubishi Tanabe has made ambitious projections for its generics operations in recent years. As recently as August, Nikkei reported Mitsubishi...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By Lisa Takagi

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By Lisa Takagi

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.